Group One Trading
VERV

Group One Trading’s Verve Therapeutics VERV Stock Holding History

Group One Trading’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-45,160
Closed -$507K – 9213
2025
Q2 		$507K Buy
45,160
+26,017
+136% +$148K ﹤0.01% 3409
2025
Q1 		$87.5K Buy
+19,143
New +$128K ﹤0.01% 4695
2024
Q4 		– Sell
-2,504
Closed -$14.1K – 8021
2024
Q3 		$12.1K Buy
2,504
+553
+28% +$3.21K ﹤0.01% 5514
2024
Q2 		$9.52K Buy
1,951
+778
+66% +$4.89K ﹤0.01% 5671
2024
Q1 		$15.6K Sell
1,173
-4,110
-78% -$54.5K ﹤0.01% 5604
2023
Q4 		$73.6K Buy
5,283
+3,930
+290% +$48.7K ﹤0.01% 4736
2023
Q3 		$17.9K Buy
+1,353
New +$21.8K ﹤0.01% 5962
2023
Q1 		– Sell
-82
Closed -$1.61K – 8014
2022
Q4 		$1.59K Buy
+82
New +$2.17K ﹤0.01% 6728

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Group One Trading's VERV Position: Q3 2025 in Review

Group One Trading sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 45,160 shares — an estimated $507K sold.

Group One Trading first reported a position in VERV in Q4 2022 and held it in 8 quarters. The position peaked at $507K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Group One Trading reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Group One Trading sold 45,160 Verve Therapeutics shares in Q3 2025, an estimated $507K.
  • Group One Trading first reported a position in Verve Therapeutics in Q4 2022 and held it in 8 quarters.
  • Group One Trading's Verve Therapeutics position peaked at $507K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Group One Trading's 13F filing for Q3 2025, filed 12 Nov 2025.